Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

Table 1 Demographic Characteristics

	Full Analysis Set (n = 185)	Per-Protocol Set (n = 125)
Characteristic at baseline
Age, years	77.6 (8.5)	78.2 (8.0)
Female, n (%)	109 (58.9)	79 (63.2)
Duration of nAMD, months	8.5 (7.3)	7.4 (3.3)
Characteristic before any treatment, including ranibizumab
BCVA, ETDRS letters	62.4 (16.6)^a	64.0 (15.6)
CRT, μm	368.3 (124.4)^b	362.4 (115.2)^c
Subretinal fluid, n (%)	133 (76.9)^b	92 (74.2)^c
Intraretinal fluid, n (%)	76 (43.9)^b	55 (44.4)^c
Pigment epithelium detachment, n (%)	125 (72.3)^b	88 (71.0)^c

Mean (standard deviation) unless otherwise stated
^an = 163; ^bn = 161; ^cn = 116; values correspond to assessments before any treatment, including ranibizumab, had been administered
BCVA Best-corrected visual acuity, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, nAMD Neovascular age-related macular degeneration

ISSN: 1471-2415